ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits?

We recently published 10 Stock With Eye-Popping Gains; 5 Are on Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Thursday.

ImmunityBio extended its winning streak to a 10^th consecutive day on Thursday, soaring 30.79 percent to close at $3.95 apiece, as investors loaded portfolios after achieving a 700 percent jump in preliminary revenues from Anktiva for the full-year 2025.

During the period, ImmunityBio Inc. (NASDAQ:IBRX) said that it registered $113 million in revenues from Anktiva amid strong demand. Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer.

In the fourth quarter alone, ImmunityBio Inc. (NASDAQ:IBRX) posted $38.3 million in net revenues, marking a 431 percent increase from the same period last year.

“ImmunityBio continues to see increased sales momentum supporting a trend of increases quarter-over-quarter with a 54 percent quarter over quarter unit volume growth rate during FY 2025,” it said.

In other recent news, ImmunityBio Inc. (NASDAQ:IBRX) has secured the approval of the Saudi Food and Drug Administration to sell and market Anktiva, in combination with an immune checkpoint inhibitor, in Saudi Arabia.

“This approval represents a significant step forward for lung cancer patients in the Kingdom of Saudi Arabia and a meaningful milestone that we hope will pave the way toward additional approvals across a region where lung cancer claims far too many lives each year,” said Executive Chairman Patrick Soon-Shiong.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.